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Abstract
RanBPM is a highly conserved protein that has been shown to impact numerous cellular
processes including migration, proliferation, and apoptosis. RanBPM exists in a multi-protein
complex called the CTLH complex, which functions as an E3 ubiquitin ligase. A putative
member of the CTLH complex, WDR26, has been implicated in the Wnt pathway through
regulating β-catenin protein levels. This study investigated whether β-catenin regulation is
performed by the CTLH complex. WDR26 was confirmed as part of the CTLH complex, and
this complex is interacting with Axin1. CTLH members RanBPM and RMND5A both
regulate beta-catenin levels in a proteasome dependent manner. Additionally, this regulation
affected downstream expression of β-catenin target genes. Together these results have
revealed a potential target of the CTLH complex and suggests a novel mechanism that
regulates Wnt signalling. This study has revealed new insights into the CTLH complex
functioning as a novel tumour suppressor.

Keywords
RanBPM, RMND5A, CTLH Complex, Ubiquitination, Protein Regulation, Degradation, Wnt
Pathway, β-catenin.
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Chapter 1
1

Introduction

1.1 Cancer
Cancer is one of the leading causes of death in Canada, and it is estimated that one in two
Canadians will develop cancer within their lifetime with one of four dying of the disease
(1). Over the past three decades, the advancement in technology and scientific research of
cancer has decreased the mortality rates for all forms of cancer (1). In spite of decreasing
mortality rates, cancer-related deaths have been increasing and are expected to continue
as our population grows in number and age (1). To combat this increased incidence,
further advancements must be made into understanding the complex disease of cancer to
provide more effective diagnoses and treatments.
Initially, tumorigenesis was only linked to genomic alterations such as single
deoxyribonucleic acid (DNA) mutations or the complete loss or duplication of genetic
material (2). However, recent discoveries in the growing field of epigenomics has
revealed that epigenetic changes such as DNA methylation, histone acetylation, or
chromosomal rearrangement also promote tumorigenesis (3). It is the multi-step
accumulation of these genomic and epigenomic changes that promotes the transformation
of a normal human cell to a cancerous cell (3). During carcinogenesis, there are six
targeted processes commonly altered presenting what we know as the six hallmarks of
cancer (4). These hallmarks consist of: the abilities to evade growth suppression, resist
cell death, enable replicative immortality, provide sustained proliferative signalling,
induce angiogenesis and promote invasion and metastasis (4). While each hallmark may
individually contribute to cancer progression, not all are required for the transformation
of a normal cell to cancerous cell (4). Different hallmarks may be displayed within a
heterogeneous collection of cancer cells, while the same cell may display different
hallmarks at different times of cancer progression (4). Thus, each cancer may display a
unique and changing pattern of hallmarks and genomic alterations increasing the
complexity of, and difficulty in treating cancer. To effectively treat cancer, we need to
understand the underlying mechanism of how a cell activates these hallmark pathways.
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While many proteins and targets have already been identified and used to design new
strategies for cancer therapy, there is still much to discover. This study investigates the
role that the Ran-binding protein microtubule organization center (RanBPM) plays in the
regulation of the signal transduction molecule beta-catenin (β-catenin) of the winglessintegrated (Wnt) pathway.

1.2 RanBPM
1.2.1

Overview

RanBPM, also known as RanBP9, was originally identified in 1998 through a yeast twohybrid assay as a 55 kDa protein and the ninth member of the Ras-related nuclear (Ran)
protein family (5). Ran proteins are guanosine triphosphatases (GTPases) of the rat
sarcoma (Ras) superfamily and are involved in nuclear transport during interphase,
mitotic spindle formation during mitosis, and are co-activators of the androgen receptor
(6). RanBPM was first reported to interact with Ran, localize to the centrosome and was
believed to assist in microtubule nucleation (5).
These findings were later dismissed as it was discovered the 55 kDa protein was a
truncated version of the full length 90 kDa RanBPM (7). The full length RanBPM only
weakly interacted with Ran and no longer localized to the centrosome (7). Instead, the
full length RanBPM was found to be a ubiquitously expressed nucleocytoplasmic protein
possessing a number of highly conserved domains, however these did not confer any
enzymatic activity (8). Since its discovery, RanBPM has been demonstrated to influence
several cellular processes including apoptosis, cell adhesion and migration, gene
transcription and metastasis (9-23). Although it has no enzymatic activity, RanBPM
instead functions as a scaffold protein and impacts these pathways through mediating
protein-protein interactions (22, 24).

1.2.2 Conserved Domains and Structure
RanBPM has five conserved domains that contribute to its protein-protein interactions;
the N-terminal proline-glutamine domain, the spore lysis A and ryanodine receptor
domain (SPRY), the lissencephaly type-1-like homology domain (LisH), the C-Terminal
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to LisH domain (CTLH) and the C-terminal CT11-RanBPM domain (CRA) (Figure 1.1)
(25). The N-terminal domain of RanBPM consists of a highly disordered proline and
glutamine rich region (7). Polyglutamine proteins have previously been described to be
pathogenic and form aggresomes around the centromere and attributed to
neurodegenerative disease (26, 27). While RanBPM does contribute to aggresome
formation, it is known that it achieves this by interacting with histone deacetylase 6
(HDAC6) via the LisH/CTLH domains (28).
Additionally, the proline rich region of the N-terminal domain contains six SH3-binding
domains, which are predicted to have high affinity for the sarcoma (Src) and growth
factor receptor bound protein 2 (Grb2) proteins (29, 30). The SPRY domain was first
identified as being homologous to regions within the Dictyostelium discoideum, spore
lysis A (SplA) kinase and the mammalian ryanodine receptor calcium-release channels
(RyR) (31). The function of the SPRY domain is poorly understood, however many
SPRY containing proteins harbour a really interesting new gene (RING) domain, which
is characteristic of an E3 ubiquitin ligase (31). The LisH and CTLH domains are to the Cterminus of the SPRY domain. Both domains are predicted to have α-helical topology
and together may form a unique globular domain responsible for regulating proteinprotein interactions and microtubule dynamics (32-34). Lastly, the C-Terminal CRA
domain is predicted to have six α-helices which is characteristic of the death domain
superfamily (32).

1.2.3

Role in Transcriptional Regulation

Through its protein interacting domains, RanBPM has been demonstrated to influence
several cellular processes, including transcriptional regulation. Performing a microarray
analysis on cells stably expressing RanBPM shRNA or non-targeting control shRNA
revealed a widespread change in gene expression upon downregulation of RanBPM (19).
It was found that many genes affected had similar transcription factor binding sites in
their promoter regions. The High Mobility Group (HMG), Forkhead (FOX) and
Homeobox families of transcription factors were overrepresented among the promoters of
genes affected by RanBPM downregulation (19). These families are known to have in
important role in both development and tumorigenesis (19).
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Figure 1.1. Schematic Diagram of RanBPM. The conserved domains of RanBPM are
shown: The SPRY (spore lysis A and ryanodine receptor) domain; the LisH
(lissencephaly type-1-like homology) domain; the CTLH (C-terminal to LisH) domain;
and the CRA (CT11-RanBPM) domain. Figure is adapted from (22).
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Additionally, RanBPM has been shown to be a potent transcriptional co-activator for the
glucocorticoid (GR), androgen (AR), and thyroid hormone (TR) nuclear receptors
(21,35). RanBPM is also a cofactor for the TATA box binding protein-associated factor 4
(TAF4), a subunit of transcription factor II D (TFIID), a coactivator of several
transcription factors and nuclear receptors (36).
RanBPM was shown to interact with tropomyosin kinase A (TrkA) and negatively
regulate nerve growth factor activated nuclear factors of activated T-cells (NFAT)dependent transcription (37). Additionally, RanBPM is a negative regulator of the nuclear
factor kappa B (NF-kB) pathway. RanBPM has been reported to bind to TND receptorassociated factor 6 (TRAF6) to inhibit auto-ubiquitination and activation of NF-kB
signalling (38). Together, these exemplify the role RanBPM plays as both a positive and
negative regulator of transcriptional regulation through the direct interaction with
transcription factors or the indirect targeting of upstream trans-regulatory elements.
However, the exact mechanism of how RanBPM achieves this transcriptional regulation
remains unknown.

1.2.4

Role in Apoptosis

RanBPM has also been demonstrated to play a role in the activation of apoptosis.
RanBPM promotes cell death through caspase-3 activation mediated by the CRA domain,
which as previously mentioned resembles the death domain superfamily (10, 32).
Caspase-3 activation is regulated by B cell lymphoma 2 (Bcl-2) family proteins. These
proteins function to regulate the intrinsic apoptotic pathway through the interaction of
both inhibitors and activators of cell death (39). In response to DNA damage, proapoptotic Bcl-2 family proteins function to release cytochrome c from the mitochondrial
membrane in order to promote caspase activation and trigger cell death (39). It is through
this intrinsic pathway that RanBPM regulates apoptosis. Cells with stably downregulated
RanBPM showed increased resistance to cell death following treatment with ionizing
radiation (IR) (10). Similarly, reduced RanBPM provides resistance to chemotherapeutic
agents in gastric cancer cells (23). It was found the downregulated RanBPM cells had an
increase in expression of anti-apoptotic proteins Bcl-2 and B cell lymphoma extra large
(Bcl-XL) while there was a decrease in mitochondria-associated Bcl-2-associated X
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protein (Bax), a pro-apoptotic Bcl-2 family protein (10). Together these lead to a
significantly reduced induction of caspase-3 and apoptosis. Conversely, overexpression
of RanBPM has been shown to decrease Bcl-2 protein levels, increase Bax
oligomerization at the mitochondrial membrane increasing the permeability and release
of cytochrome c to activate apoptosis (11, 22). Lastly, overexpression of RanBPM in
transgenic mice resulted in impaired mitochondrial function, and potentiated amyloid-β
(Aβ)-induced apoptosis (40).
RanBPM’s regulation of the intrinsic apoptotic pathway may be mediated through its
protein-protein interactions with factors that regulate apoptotic activation. For instance,
RanBPM interacts with p75 neurotrophic receptor (p75NTR), a member of the tumour
necrosis factor (TNF) receptor superfamily (41). While p75NTR has a dichotomous role
in promoting both cell survival and apoptosis, it is suggested that RanBPM may act as an
adaptor protein that mediates p75NTR-induced apoptosis as it interacts with p75NTR’s
cytoplasmic death domain (41). Additionally, RanBPM is known to interact with the Cterminal domain of cyclin-dependent kinase 11 (CDK11p46) (42). CDK11p46 is the
caspase-processed product of the larger CDK11p110 isoform, and is known to promote
apoptosis, however the mechanism of CDK11p46 apoptotic activation is unclear (42).
However, in these studies, the functional outcome of RanBPM’s interaction with
p75NTR and CDK11p46 was not investigated, thus its role in influencing the apoptotic
process through these two pathways is unclear. Lastly, RanBPM interacts with and
stabilizes the tumour suppressor p73 by preventing its ubiquitination and subsequent
degradation (12). The overexpression of RanBPM was shown to increase p73 mRNA
levels and loss of RanBPM blocked p73-induced apoptosis (11). While the mechanism
may not be fully understood, these studies indicate RanBPM has a pro-apoptotic affect
and may regulate the apoptotic pathway in multiple ways.

1.2.5

RanBPM in Migration, Adhesion and Morphology

RanBPM has also been reported to regulate cellular adhesion, morphology and migration.
One way this is accomplished is through its direct interaction with the β-integrin
lymphocyte function-associated antigen-1 (LFA-1) receptor (18). Integrins have an
important role in cell adhesion and migration where they are responsible for attaching the
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cytoskeleton to the extracellular matrix (ECM) (43). They also function to transmit
information from the ECM into the cell and control the activation of several signalling
pathways (43). Overexpression of RanBPM was shown to increase endocytosis and
internalization of β-integrin proteins resulting in decreased cell adhesion and spreading
(44). Alternatively, upon knockdown of RanBPM, β-integrin levels increased at the cell
surface promoting cell adhesion and spreading (44). RanBPM also prevents focal
adhesion signalling and assembly by preventing the localization of cell adhesion proteins
to focal adhesion points (44). Similarly, RanBPM was shown to prevent cell adhesion
and affected cell morphology in female germline stem cell niche in Drosophila (13).
RanBPM also interacts with Plexin-A1 receptor, and when RanBPM was overexpressed,
cell spreading was reduced, and cells appeared irregularly contracted (45). Lastly, recent
studies have shown RanBPM to form a complex with Muskelin, and the knockdown of
either RanBPM or Muskelin resulted in an enlarged and protrusive cell perimeter (46).
RanBPM has been shown to both positively and negatively affect cell migration.
RanBPM is known to interact with the mesenchymal epithelial transition factor tyrosine
kinase (MET) and activate the extracellular signal regulated kinase (ERK) pathway,
which in turn promotes cell migration (16). On the other hand, RanBPM has been shown
to inhibit leukotriene B4 receptor 2 (BLT2)-mediated migration, where overexpression of
RanBPM inhibited chemotactic migration (47). Our laboratory has demonstrated that
downregulation of RanBPM led to increased cell migration in a wound healing scratch
assay (20). A recent study in gastric cancer cells has shown that the downregulation of
RanBPM led to a decrease in cell adhesion, increased cell migration and was commonly
found downregulated in metastatic gastric tumours compared to non-metastatic tumours
(23). Together, the function of RanBPM in maintaining adhesion and morphology and its
opposing role in migration indicate its importance for normal physiological development
as well as pathogenesis.

1.2.6

RanBPM in Cancer

As previously described, cancer progression is linked to six hallmarks including but not
limited to proliferative signalling, evasion of apoptosis, invasion and metastasis (4).
Previous studies have suggested that the dysregulation of RanBPM may promote these
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three hallmarks of cancer (9-23). The microarray analysis on cells with stably
downregulated RanBPM showed 167 differentially expressed genes, with over one third
of these genes being associated with cancer (19). Notably, pathways affected by RanBPM
downregulation included the ERK, wingless-integrated (Wnt), Notch and
phosphoinositide-3 kinase (PI3K) pathways (19). These pathways are known to regulate
proliferation, cell cycle progression, growth, survival and are commonly dysregulated in
cancer (48-51).
Further characterization of RanBPM in our laboratory has revealed a tumour suppressive
role for RanBPM through the inhibition of ERK signalling (20). RanBPM was shown to
interact with and down regulate rapidly accelerating fibrosarcoma (RAF) protein levels,
preventing its binding to heat shock protein 90 (Hsp90), subsequently preventing the
activation of ERK1 (20). This in turn downregulated anti-apoptotic BCL-2 family
proteins both at the transcriptional and protein level (10, 20). As such, downregulation of
RanBPM caused an increase in anti-apoptotic proteins, decreasing mitochondrial
permeabilization, and provided these cells the ability to evade apoptosis (10).
Additionally, studies have implicated a role for RanBPM in regulating cellular migration
and metastasis. RanBPM has been shown to interact with histone deacetylase 6 (HDAC6)
through its LisH and CTLH domains and to negatively regulate its deacetylase activity
(28). HDAC6 is a cytoplasmic deacetylase necessary to the formations of aggresomes
and when overexpressed is known to promote cellular transformation and metastasis (28,
52). Similarly, in gastric cancer cells, the downregulation of RanBPM was associated
with an increase in cell proliferation and motility (23). Additionally, metastatic gastric
cancers were shown to have lower expression of RanBPM in distant metastatic tumours
compared to non-distant metastatic tumours, further implicating RanBPM in the
regulation of metastases (23). While many reports suggest RanBPM to play a tumour
suppressive role, there have been contrasting studies suggesting it to function as an
activator of ERK signalling (16). RanBPM has been shown to interact with the tyrosineprotein kinase MET mediated its SPRY domain, inducing the guanosine triphosphate
(GTP) transfer to rat sarcoma (RAS), leading to the phosphorylation and activation of
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ERK1 (16). This indicates a more complex role of RanBPM in tumorigenesis that may be
cell-type or cancer stage dependent.

1.3 The CTLH Complex
While previous studies have looked at RanBPM in isolation, when first characterized it
was found to exist in a 670 kDa protein complex (7). This was later identified to be a
seven-member complex comprised of two-hybrid-associated protein 1 with RanBPM
(TWA1), Muskelin, armadillo repeat containing 8 (ARMC8) α and β, required for
meiotic nuclear division homologue A (RMND5A), macrophage erythroblast attacher
(MAEA) and RanBPM (Figure 1.2) (53). It was given the name the C-terminal to LisH
(CTLH) complex as each member, other than ARMC8α/β, contains a CTLH and LisH
domain (53). Apart from Muskelin, each member of the CTLH complex has a
homologous protein in Saccharomyces cerevisiae (54). Together, in S. cerevisiae these
form the glucose induced degradation deficient (GID) complex which contains WD
repeat-containing protein 26 (WDR26) or GID7, in the place of Muskelin (54). While the
initial characterization of the CTLH complex did not find WDR26, more recent studies
suggest it exists in the CTLH complex (55, 56).
The yeast GID complex is a E3 ubiquitin ligase with a role in regulating glucose
metabolism (54). When yeast cells are switched from an ethanol carbon source to a
glucose media, the GID complex becomes activated and targets fructose-1-6bisphosphatase (FBPase), a key enzyme in the gluconeogenic pathway, for ubiquitination
and subsequent proteasomal degradation (54, 57). Targeting FBPase upon reintroduction
of glucose allows yeast to utilize glycolysis over gluconeogenesis. Interestingly, three
members of the GID complex, GID1, GID4 and GID5, also participate in the vacuolar
proteolytic system, an alternative pathway which also triggers the degradation of FBPase
(58).
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Figure 1.2 Proposed topology of the CTLH complex. The CTLH complex consists of
the Scaffolding protein RanBPM (Ran binding protein microtubule organization center),
with required for meiotic nuclear division homologue A (RMND5A), macrophage
erythroblast attacher (MAEA), two-hybrid-associated protein 1 with RanBPM (TWA1),
Muskelin, armadillo repeat containing 8 α and β (ARMC8α/β), and Muskelin. Each protein
is labelled with its corresponding S. cerevisiae homologue (indicated in parentheses). It is
hypothesized to also comprise of WD repeat 26 (WDR26) and C17orf39, the mammalian
homologue to the S. cerevisiae GID4, however these have yet to be confirmed as part of
the complex. Figure adapted from (22).
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A recent study has revealed one GID member, GID4, to be the recognition component of
the GID complex (59). GID4 is absent from yeast cells when grown in ethanol, but upon
introduction of glucose it is rapidly synthesized which coincides with the degradation of
FBPase (59). It was determined that GID4 specifically recognizes the N-terminal proline
of FBPase, as well as recognizing and targeting isocitrate lyase (Icl1) and malate
dehydrogenase (Mdh2), two additional gluconeogenic enzymes, for ubiquitination (59).
Two members of the GID complex, GID2 (RMND5A) and GID9 (MAEA), contain
RING zinc finger domains, which is the functional domain conferring E3 ubiquitin ligase
activity (54, 60, 61). RING-type E3 ligases function together with an E2 ubiquitinconjugating enzyme to mediate the transfer of a ubiquitin onto a target substrate (61).
While both GID subunits contain RING domains, only GID2 has successfully been
shown to have in vitro ubiquitin ligase activity (54, 60). However, GID9 is required for
GID2 ubiquitination activity in vivo, as mutations made to the RING domain of GID9
abolishes the FBPase ubiquitination by GID2 following a switch to a glucose-rich media
(60).
While the GID complex appears to be conserved in the mammalian CTLH complex,
which also contains two RING domain containing proteins, RMND5A (GID2) and
MAEA (GID9), the mammalian complex has yet to be shown to contain ubiquitination
activity in vivo (25). However, recently through reconstituting each member, the CTLH
complex ubiquitination activity has been demonstrated in vitro with HMG box-containing
protein 1 (Hbp1) as a substrate (62).
A number of studies have also implicated components of the CTLH complex in the
regulation of β-catenin (13, 19, 56, 63, 64). The putative CTLH member, WDR26, has
previously been shown to interact with Axin1 and regulate β-catenin protein levels (63).
A separate interactome study has revealed that WDR26, and all CTLH members to be an
interacting partner with Axin1 (56). As previously mentioned, our laboratory has
demonstrated that the downregulation of RanBPM results in dysregulation of genes
within the Wnt signalling pathway (13). RanBPM has been shown to regulate β-catenin
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protein levels in Drosophila, and ARMc8α has been shown to interact with β-catenin and
regulate α-catenin protein levels (19, 64). These previous studies implicating the CTLH
complex with β-catenin regulation raises the question whether it could be a novel target
of CTLH ubiquitination.

1.4 Ubiquitination Overview
The ubiquitination pathway provides an essential post-translational modification that
regulates cellular signalling and protein turnover (65). Ubiquitin is a small 8.5 kDa
protein that can be covalently linked to lysine residues of a protein substrate including
itself (66). The addition of a single ubiquitin (mono-ubiquitination) can affect protein
stability, cellular localization and protein-protein interactions (67, 68). Addition of
multiple, or polyubiquitination, serves as a signal to target proteins for degradation by the
26S proteasome (69). This process requires three enzymes: ubiquitin activating enzymes
(E1), ubiquitin conjugating enzymes (E2) and ubiquitin-protein ligases (E3) (70). The E1
activating enzyme uses adenosine triphosphate (ATP) to form a thiol-ester bond with the
ubiquitin protein at its carboxyl terminus activating the ubiquitin. The activated ubiquitin
is transferred to a E2 conjugating enzyme which transiently carries the ubiquitin and
recruits an E3 ubiquitin ligase. The E3 ubiquitin ligase then transfers the ubiquitin from
the E2 enzyme onto a specific lysine residue of a target substrate (70). The specificity of
ubiquitination is driven by E3 ubiquitin ligases, of which over 600 are encoded in the
human genome giving a diverse range of target substrates influencing a number of
processes including protein trafficking, DNA repair and cell signalling (65). One pathway
that is regulated by ubiquitination is the canonical Wnt signalling pathway.

1.5 The Wnt Signalling Pathway
1.5.1 β-Catenin Overview
β-catenin is a 90 kDa, multi-functioning protein that is involved in both the regulation of
gene transcription and cellular adhesion (71, 72). β-catenin was first discovered as an
interacting partner to the cadherin family of proteins (73). Cadherins are a family of cell
adhesion molecules that promote cell-cell adhesion through the formation of adherens
junctions (74). β-catenin has been shown localize to adherens junctions and interact with
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the cytoplasmic tail of E-cadherin forming a Cadherin-β-catenin complex (75, 76). It is
thought that β-catenin indirectly mediates the interaction of the actin cytoskeleton with Ecadherin to promote cell-cell contact, and the loss of E-cadherin-β-catenin complex
formation has been associated with increased epithelial-to-mesenchymal transition
(EMT) (77).
Since its discovery, β-catenin has also been shown to play a crucial role in the Wnt
signalling pathway (78). The Wnt signalling pathway is a key regulator of cellular
proliferation, differentiation and is critical for embryonic development (72). β-catenin is
required for the activation of Wnt targeted gene expression, and the dysregulation of βcatenin/Wnt signalling has been closely linked to the progression of Familial
Adenomatous Polyposis (FAP), among various forms of cancer (79). See figure 1.3 for an
overview of Wnt signalling and the regulation of β-catenin.

1.5.2 β-catenin regulation
In the absence of Wnt ligand, or in the Wnt “off” state, β-catenin is under strict regulation
by the Axin degradation complex consisting of the proteins Adenomatous Polyposis Coli
(APC), Glycogen Synthase Kinase 3-beta (GSK3β) and Casein Kinase 1 (CK1) all bound
to the Axin1 scaffolding protein (80). Together, this protein complex works to
sequentially phosphorylate β-catenin at serine-45 (S45) by CK1 followed by GSK3β
phosphorylation at threonine-41 (T41) and serine-33 and -37 (80, 81). This
phosphorylation pattern is recognized by the beta-transducin repeat containing E3
ubiquitin protein ligase (β-TrCP) which ubiquitinates and promotes β-catenin for
degradation by the proteasome (82). While β-TrCP is the most common E3 ubiquitin
ligase associated with β-catenin regulation, additional E3 ubiquitin ligases including
Seven in Absentia Homologue 1 (SIAH-1) and the E3 ubiquitin ligase identified by
Differential Display (EDD), have been shown to ubiquitinate β-catenin, revealing a more
diverse mechanism to β-catenin regulation (83, 84).

1.5.3 Activation of Wnt signalling
The activation of the canonical Wnt signalling pathway occurs by one of six Wnt ligands
(Wnt3, Wnt4, Wnt5b, Wnt7a, Wnt10a and Wnt10b) and requires both the Frizzled (Fz)
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and the LDL receptor-related proteins 5 and 6 (LRP5/6) receptors (72, 85, 86).
Stimulation by Wnt ligands causes these receptors to form a Wnt-Fz-LRP5/6 complex
and in turn recruits the intracellular scaffolding protein Dishevelled (Dvl) (87, 88). Dvl
promotes the oligomerization of individual Wnt-Fz-LRP5/6 complexes at the cell
membrane (88). LRP5/6 contains five PPPSPxS (P: Proline; S: Serine or Threonine; x:
variable) phosphorylation motifs mimicking that of β-catenin (89). When these receptors
are aggregated, the Axin degradation complex has a high affinity for these PPPSPxS
motifs and will move to the cell membrane to phosphorylate LRP5/6. This essentially
sequesters the Axin degradation complex at the cell membrane, allowing for β-catenin to
accumulate (81, 90).
While the stabilization of β-catenin protein levels coincides with an increased nuclear
presence, the exact mechanism for β-catenin translocation into the nucleus is not fully
understood. It has been suggested that β-catenin contains a nuclear localization signal
(NLS) and thus enters directly into the nucleus through nuclear pore proteins while βcatenin co-activators increase its retention in the nucleus (91, 92). More recent studies
show that in addition to stabilization of β-catenin protein levels, activation of Ras-related
C3 botulinum toxin substrate 1 (Rac1) is also required for β-catenin nuclear import (93).
It is suggested that Rac1 forms a cytoplasmic complex with Jun N-terminal kinase 2
(JNK2) and β-catenin, and JNK2 phosphorylates β-catenin at serine 191 and 605
(S191/S605) promoting its nuclear import (93).
Upon nuclear translocation, β-catenin interacts with the T-cell factor/lymphoid enhancer
factor (TCF/LEF) family of transcription factors (94). TCF/LEF proteins are HMG DNAbinding factors that target and bind to Wnt responsive element (WRE) DNA sequences
(95). In the absence of β-catenin, the TCF/LEF proteins interact with transducin-like
enhancer 1 (TLE1) which functions to promote histone deacetylation of WREs, causing
chromatin compaction and inhibiting gene expression (96). When interacting with
TCF/LEF proteins, β-catenin directly displaces TLE1 and recruits a host of co-activators,
including chromatin remodeling proteins and histone acetyltransferases (HAT), to enable
gene expression (97, 98).
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Figure 1.3 Overview of β-catenin regulation. A) In the absence of a Wnt signal, βcatenin is under strict regulation by the Axin degradation complex, which consists of the
scaffolding protein Axin along with APC (adenomatous polyposis coli) protein, CK1
(casein kinase 1) and GSK3β (glycogen synthase kinase 3-beta). The Axin degradation
complex functions to sequentially phosphorylate β-catenin. This phosphorylation is
identified by the E3 ubiquitin ligase β-TrCP (beta-transducin repeat containing E3
ubiquitin protein ligase), which polyubiquitinates β-catenin promoting it for degradation
by the 26S proteasome. B) In the presence of a Wnt signal, the receptors LRP5/6 (LDL
receptor-related proteins 5 and 6) and Frizzled dimerize and recruit the protein Dvl
(Dishevelled). Dvl functions to recruit and sequester the Axin degradation complex at the
cell membrane, allowing for β-catenin to accumulate, translocate into the nucleus where
it activated Wnt target gene expression. Figure adapted from (72).
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The dysregulation of β-catenin signalling has been associated with numerous forms of
cancer including but not limited to colorectal cancer, hepatocellular carcinoma, ovarian
cancer and melanoma (72, 79, 85). The oncogenes MYC and CCND1 contain WREs and
have been identified as targets of β-catenin signalling (99, 100). C-Myc is a key regulator
for both cellular proliferation and metabolism while cyclin D1 is a key regulator of cell
cycle progression, and individually can promote cancer progression when dysregulated
(100, 101). Given β-catenin’s role in regulating these oncogenic pathways, it is crucial to
identify novel therapeutic mechanisms to potentially downregulate β-catenin.

1.6 Hypothesis and Objectives
Several studies have revealed CTLH members to interact with components of the Wnt
signalling pathway and to regulate β-catenin levels, however how this regulation is
achieved has yet been investigated. Thus, I hypothesize that the CTLH complex is an
additional E3 ubiquitin ligase regulating the Wnt signalling pathway through the
targeting of β-catenin for degradation. The outcome of this study is to address the
following objectives:
1) To show that the putative member, WDR26, is part of the CTLH complex and this
complex is interacting and/or co-localizing with Axin
2) To determine whether the CTLH complex regulates β-catenin protein levels
3) To determine whether the CTLH complex regulates Wnt/β-catenin target-gene
expression
This work could potentially provide a novel way to target β-catenin for regulation,
revealing a potential new therapeutic strategy in treating cancers characterized with
oncogenic mutations in β-catenin/components of the Wnt pathway. The research
performed in this study will examine the possible tumour suppressor role that the CTLH
complex plays in negatively regulating Wnt/β-catenin signalling.
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Chapter 2
2

Materials and Methods

2.1 Chemical Reagents
2.1.1

DNA Constructs and Cloning

pCMV-HA was purchased from ClonTech Laboratories Inc. (Currently known as Takara
Bio USA, Inc.), pCMV-HA-RanBPM was provided by Dr. Mark Nelson (University of
Arizona, Tucson, AZ, USA). pCDNA3.1-HIS-FLAG-WDR26 was provided by Dr.
Songhai Chen (University of Iowa, Iowa City, IA, USA). A pGL3 luciferase vector
containing a concatemer of 12 consecutive TCF response elements upstream of
Promega’s MinP minimal promoter, designated β-catenin Activate Reporter Luciferase
(pBARL) was provided by Dr. Greg Kelly (University of Western Ontario, London, ON,
Canada). pSV40-Renilla was purchased from Promega. The pCGN-HA-RMND5A was
prepared by a previous Schild-Poulter Laboratory member by polymerase chain reaction
(PCR) amplifying RMND5A from a complementary DNA (cDNA) library. RMND5A
was ligated into a pCGN-HA vector using the enzymes BamH1 and Xba. A pCMV-HAUbiquitin was received from Dr. Lina Dagnino (University of Western Ontario, London,
ON, Canada).

2.1.2

In vitro assays

Sodium chloride (NaCl), potassium chloride (KCl), ethylenediaminetetraacetic acid
(EDTA), hydroxyethyl piperazineethanesulfonic acid (HEPES), Tris-hydroxymethyl
amino methane (Tris), hydrochloric acid (HCl), Tween-20 and sodium dodecyl sulphate
(SDS) were purchased from Wisent Inc. (St. Bruno, QC, Canada). Nonidet P-40 (NP-40),
TritonX-100 (TX100), phenylmethylsulfonyl fluoride (PMSF), dithiothreitol (DTT),
leupeptin, aprotinin, pepstatin, sodium fluoride (NaF) and sodium orthovanadate
(Na3VO4) were purchased from Bioshop Inc. (Burlington, ON, Canada). Glycerol was
purchased from Caledon Laboratory Chemicals Ltd. (Georgetown, ON, Canada).
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2.2 Cell Culture, Transfections and Treatments
HeLa and HCT 116 cells were purchased from the American Type Culture Collection
(ATCC). HeLa and HCT 116 cell lines stabling expressing RanBPM short-hairpin
(shRNA) or non-targeting control shRNA were generated as previously described in (10,
20). The cell lines were grown in high-glucose DMEM (DMEM) (Wisent Inc.)
supplemented with 8% fetal bovine serum (FBS) (Wisent Inc.), 1% sodium pyruvate
(Wisent Inc.), 1% L-glutamine (Wisent Inc.) and 4.5 g/L glucose and incubated at 37O C
and 5% CO2. To maintain stable selection the HeLa and HCT 116 shRNA cells were
grown in 0.35 g/L G418 sulphate (Bioshop Inc). Immortalized mouse embryonic
fibroblasts (MEFs) deficient for RanBPM were generated by Schild-Poulter laboratory
member Xu Wang using methods previously described (102). Mouse embryonic
fibroblasts were grown in high-glucose DMEM with the same supplementation as above,
with G418 sulphate being replaced with 0.1 mM of beta-mercaptoethanol (βME). CaCo2
cells were generously provided by Dr. Tirona Rommel (University of Western Ontario,
London, ON, Canada) and were grown in before mentioned high-glucose conditions
supplemented with 1% penicillin-streptomycin (450-201-EL; Wisent Inc.). For a full list
of cell lines used refer to Table 2.1.
Cells were cultured onto 6 or 10 cm plates for transfection and protein isolation. Plasmid
transfections were performed using JetPRIME® Transfection Reagent (PolyPlus
Transfection) according to the manufacturer’s protocol. The amount of DNA used for
each transfection is provided in figure legends. pBS-SK (Agilent Technologies) was used
to supplement transfected DNA to the minimum amount if required.
CaCo2 cells were treated using RanBPM short-interfering RNA (siRNA) (AM16708A;
Ambion) or control siRNA (4390843; Ambion) at a concentration of 10 nM. Ncarbobenzoxyl-L-leucinyl-L-leucinyl-L-leucinal (MG-132) (Bioshop Inc.) treatments
were performed using MG-132 or dimethyl sulfoxide (DMSO) (Bioshop Inc.) as a
vehicle at 10 μM for 6-24 h.
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Table 2.1 List of cell lines used with cell type of origin and gene status of CTLH
members, β-catenin and APC. Β-catenin and APC status adapted from (112).
Cell Type

HeLa

Origin of Cell

CTLH Member
Status

Β-catenin Status

APC Status

Cervical
Carcinoma

Wild-Type

Wild-type

Wild-Type

Wild-Type

Mutant

RanBPM
downregulated
RMND5A -/HCT116

Colorectal
Carcinoma

Wild-Type
RanBPM
Downregulated

CaCo-2

Mouse
Embryonic
Fibroblast

Colorectal
Carcinoma

Wild-Type

Mutant

Mutant

Fibroblast

Wild-Type

Wild-Type

Wild-Type

RanBPM -/-
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2.3 HeLa RMND5A CRISPR Knockout Clones
Required For Meiotic Nuclear Division 5 Homolog A (RMND5A) CRISPR knockouts
were generated by Schild-Poulter laboratory members Xu Wang and Matthew Maitland.
Single-guide RNA (sgRNA) were designed against exon 3 of RMND5A using
www.benchling.com (On-target score = 65.7, Off-target score = 86.0). Top and bottom
oligomers (5’ – CACCGTGGAGCACTTCTTTCGACA – 3’; 5’ –
AAACTGTCGAAAGAAGTGCTCCAC – 3’) were annealed together and ligated with
pSpCas9(BB)-2A-Puro (PX459) V2.0 that was digested with BpiI. Early passage wildtype HeLa cells were seeded on 12-well dishes and transfected with 800 ng of plasmid
DNA. Forty-eight hours post-transfection, cells were put under puromycin selection for
seven days. Afterwards, remaining single cells were transferred to a 48-well dish and
expanded. Loss of RMND5A protein was confirmed by Western blot and DNA mutation
was confirmed and the top off-target sites were checked for absence of mutations through
sequencing.

2.4 Preparation of Cell Extracts
HeLa, HCT 116, MEF and CaCo2 cells were grown in 6 or 10 cm culture dishes to
approximately 80% confluency. Briefly, the cells were washed thrice with cold phosphate
buffered saline (PBS) (Wisent Inc.) and were scraped into a small amount of the final
wash for collection. Cells were pelleted by centrifugation for 5 minutes at 8000rpm. The
supernatant was removed, and the cell pellets were lysed on ice for 25 minutes in whole
cell extract (WCE) buffer (150 mM NaCl, 1 mM EDTA, 50 mM HEPES pH 7.4, 10%
glycerol, 0.5% NP-40, and 0.5% TX100), or radioimmunoprecipitation assay (RIPA)
buffer (140 mM NaCl, 1 mM EDTA, 10 mM Tris-HCL pH 8.0, 1% TX100, 0.1% sodium
deoxycholate, and 0.1% SDS) supplemented with 0.1 mM PMSF, 1 mM DTT, 2 μg/mL
leupeptin, 10 μg/mL aprotinin, 2.5 μg/mL pepstatin, 2 mM NaF and 2 mM Na3VO4. After
lysis the cells were centrifuged for 20 minutes at 13,000 rpm at 4O C and the resulting
supernatant was collected. Protein concentration was then quantified using a Bradford
Protein Assay (Bio-Rad) according to the manufacturer’s protocol on an LKB Ultraspec
4050 (Biochrom).
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2.5 Western Blot Analysis
Up to 50 μg of protein was resolved using SDS-polyacrylamide gel electrophoresis (SDSPAGE). Following separations, gels were transferred to polyvinylidene fluoride (PVDF)
membranes using a semi-dry Trans-Blot® Turbo (Bio-Rad) transfer system at 25V for 25
minutes. Membranes were blocked in 5% skim milk dissolved in Tris-buffered saline
with Tween-20 (TBS-T; 20 mM Tris-HCl pH 8.0, 0.15 M NaCl, 0.05% Tween-20) at
room temperature for 1 h or overnight at 4O C. Primary antibodies were hybridized
overnight at 4O C, or 2 h at room temperature. After primary hybridization, the
membranes were washed three times in TBS-T for 10 minutes. Secondary antibodies
were incubated at room temperature for 1 h, followed by another three 10-minute TBS-T
washes. Membranes were developed using Clarity Western ECL Substrate (Bio-Rad
Laboratories Inc.) and imaged using a ChemiDoc MP (Bio-Rad Laboratories Inc.).
Resulting images were analyzed using Image Lab software (Bio-Rad Laboratories Inc.).

2.6 Antibodies
2.6.1 Primary Antibodies
Primary antibodies used were β-Catenin (610154; BD Transduction Laboratories), Axin1
(C76H11; Cell Signaling Technology), Vinculin (E1E9V; Cell Signaling Technology),
Beta-Actin (I-9; sc-1616-R; Santa Cruz), Human influenza hemagglutinin (HA; H9658;
Sigma-Aldrich), FLAG (M2; F1804; Sigma-Aldrich), RanBPM (71-001; BioAcademia),
RMND5A (NBP1-92337; Novus Biologicals), MAEA (AF7288; R&D Systems), ArmC8
(E-1; sc-365307; Santa-Cruz), Muskelin (C-12; sc-398956; Santa-Cruz), and WDR26
(ab85962; Abcam). Antibody concentrations can be found in Table 1.1.

2.6.2 Secondary Antibodies
Secondary antibodies used were peroxidase-conjugated AffiniPure Goat anti-Mouse IgG
(H+L; Jackson ImmunoResearch Laboratories Inc.), Blotting Grade Goat anti-Rabbit IgG
Horseradish Peroxidase Conjugate (H+L; Bio-Rad Laboratories Inc.), and Rabbit AntiSheep IgG Horseradish Peroxidase Conjugate (H+L; Bio-rad Laboratories Inc.). All
secondary antibodies were used at a 1:5000 dilution.
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Table 2.2 Concentrations used for primary antibodies in Western Blot Analysis
Antibody

Species

Dilution

β-Catenin

Mouse

1:5000

Axin1

Rabbit

1:2000

Β-Actin

Mouse

1:5000

Vinculin

Rabbit

1:10,000

HA

Rabbit

1:2000

FLAG

Mouse

1:2000

RanBPM

Rabbit

1:2000

RMND5A

Rabbit

1:100

MAEA

Sheep

1:250

Armc8

Mouse

1:100

Muskelin

Mouse

1:250

WDR26

Rabbit

1:1000
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2.7 In vitro Experiments
2.7.1 Immunoprecipitation Experiments
For co-immunoprecipitation experiments, 1 mg of total protein was used and
immunoprecipitates were isolated with Dynabeads Protein G (Invitrogen). Every 500 μL
of protein lysate was diluted with 800 μL of binding buffer (150 mM NaCl, 25 mM
HEPES pH 7.9, 0.5 mM EDTA, 12% glycerol and 0.1% NP-40) supplemented with 0.1
mM PMSF, 1 mM DTT, 2 μg/mL leupeptin, 10 μg/mL aprotinin, 2.5 μg/mL pepstatin, 2
mM NaF and 2 mM Na3VO4. Samples were pre-cleared for one hour using one-eighth of
total Dynabead Protein G volume. Pre-clear beads were removed, and the samples were
incubated with up to 7 μg of FLAG (M2; F1804; Sigma-Aldrich) or RanBPM (F-1; sc271727; Santa-Cruz) antibodies overnight at 4O C. Beads were washed three times with
an immunoprecipitation (IP) wash buffer (25 mM HEPES pH 7.9, 60 mM KCl, 0.5 mM
EDTA, 0.25% NP-40 and 2% glycerol). Beads were resuspended in SDS loading dye
(0.105 g/mL SDS, 0.093 g/mL DTT, 0.35 M Tris-HCl pH 6.8, and 30% glycerol). The
samples were then resolved and analyzed through western blot methods.
For in vitro ubiquitin assays, wild-type and RMND5A CRISPR knockout cells were
transfected with a pMT123-HA-Ubiquitin plasmid. Twenty-hour hours after transfection,
cells were incubated with 10 μM MG132 for 6 hours. Cells were lysed in denaturing
buffer (50 mM Tris-HCL pH 8.0, 150 mM NaCl, 1% Triton-X, 1% SDS,10 mM NaF, 1
mM Na3VO4 and 25 mM NEM (N-Ethylamalide, Bioshop Canada, Burlington, ON,
Canada)), and passed through a 23G needle ten times and incubated on ice for 30
minutes. Lysates were diluted 1:10 in buffer A (50 mM Tris-HCL pH 8.0, 150 mM NaCl,
1% Triton-X, 10 mM NaF, 1 mM Na3VO4 and 25 mM NEM) and incubated in primary βcatenin antibody overnight at 4 OC, followed by incubation with Dynabeads for 1 hour.
Beads were washed 3 times with buffer A, resuspended and bolding in SDS loading dye
and separated through SGS-Page and analyzed through western blot methods.

2.7.2

Immunofluorescence

Cells were seeded onto coverslips in a 24-well plate and incubated overnight. Cells were
washed three times in cold PBS then fixed using 4% paraformaldehyde for 15 minutes.
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Cells were permeabilized in 0.5% Triton-X100 for 10 minutes then blocked in 5% FBS
diluted in PBS for 1 h at room temperature. Coverslips were incubated with β-Catenin
(610154; BD Transduction Laboratories) antibody overnight at 4O C with agitation.
Coverslips were washed three times with cold PBS then incubated in the dark with antimouse Alexa Fluor 488 (Invitrogen) for 1 hour. Cells were washed again three times with
cold PBS then mounted using ProLong® Gold antifade with DAPI (Invitrogen).
Visualization was performed using an Olympus BX51 microscope with a 40x objective
and images were taken using Image-Pro Plus software (Media Cybernetics Inc.). For each
experiment, at least 50 cells analyzed and quantified using ImageJ software.

2.7.3

Luciferase Assay

5 x 104 cells were seeded into a 6-well plate and incubated overnight. Cells were cotransfected with pGL3-BARL and either pCMV-HA-Empty Vector or pCGN-HARMND5A. Cells were also transfected with either pSV40-Renilla or pCMV-βGalactosidase as internal controls to normalize luciferase levels. Luciferase activity was
measured using the Luciferase Assay System (E1500; Promega). Cells were collected 48
h after transfection and lysed in 1X Cell Culture Lysis Reagent for 15 minutes at room
temperature. Immediately following lysis, 40 μL of cell lysates were added to 50 μL of
Luciferase Assay Reagent in a 96-well micro-plate and activity was quantified using an
Orion Microplate Luminometer (Berthold Detection Systems). Beta-galactosidase
activity was measured using a Beta-Glo Assay System (E4270; Promega). Separately, 40
μL of cell lysate was added to 50 μL of Beta-Glo® Reagent and incubated for 30
minutes. Beta-galactosidase activity was quantified using an Orion Microplate
Luminometer. pBARL luciferase activity was normalized to the β-galactosidase levels.

2.8 Statistical Analysis
Statistical analyses were performed using GraphPad PRISM (GraphPad Software Inc.).
One-way analysis of variance (ANOVA) was used to compare multiple groups and twosample t-test assuming equal variance was used to compare individual groups. Graphed
data are presented as mean  standard deviation (SD). Values were determined to be
significant when p < 0.05.
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Chapter 3
3

Results

3.1

Overview

The GID homologue of the CTLH complex in S. cerevisiae is a well-documented E3
ubiquitin ligase that is responsible for promoting the polyubiquitination and proteasomal
degradation of multiple gluconeogenic enzymes including FBPase, Icl1 and Mdh2 (54,
57, 59). GID1, the yeast counterpart of RanBPM, was shown to be crucial for this
ubiquitination, as altering either the SPRY, LisH or CTLH domain of GID1 impaired the
ubiquitination of FBPase. In addition to GID1, the RING domain containing subunits
GID2 and GID9 were also required and conferred the enzymatic activity of the complex
(54). Since these components are highly conserved to the mammalian CTLH complex, it
is theorized that the CTLH complex may also function similarly as an E3 ubiquitin ligase
(25). Despite being highly conserved, the CTLH complex has only recently been
demonstrated to contain ubiquitination activity, and thus far only Hbp1 has been
identified as a substrate (62). Hbp1 is not a gluconeogenic enzyme, so this suggests the
CTLH complex may regulate different pathways than its S. cerevisiae homologue.
Previous studies have implicated multiple members of the CTLH complex to regulate βcatenin, the signal transducer of the Wnt signalling pathway. As mentioned, the putative
CTLH member WDR26 has been shown to interact with Axin1, and over expression of
WDR26 caused a decrease in β-catenin protein levels (63). A separate study also showed
that RanBPM regulates β-catenin in Drosophila where an increase in β-catenin protein
levels were observed in RanBPM mutant cells (13). Together, this suggests that β-catenin
may be regulated by the CTLH complex. However, we must first ascertain that WDR26
is part of the CTLH complex.
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3.2 WDR26 is part of the CTLH complex
3.2.1

Disrupted WDR26 and core CTLH members show similar
pattern of target tissues

Proper regulation of cell growth is maintained by cross-talk of intra- and extracellular
signalling pathways including the Tumor protein 53 (p53), ERK and Wnt signalling
pathways (103). Each has multiple components responsible for regulating pathway
activation, but in many cases only one component is needed to be dysregulated for
pathogenesis to occur. In context of the Wnt pathway, pathogenesis occurs through the
activation of β-catenin, however this can occur through multiple mechanisms. Wnt
pathway activation has been reported though activating mutations in β-catenin as well as
dysregulation of components in the Axin degradation complex (112). Separate cases have
demonstrated that deletion of Axin, GSK3β or APC causes the upregulation of β-catenin
(112). Furthermore, dysregulation of Axin, GSK3β and APC commonly result in the
development and progression of hepatocellular and colorectal carcinoma’s (117-119).
This suggests that proteins within one pathway, or complex, when dysregulated lead to a
similar pathogenic outcome. Thus, we sought to determine the pathogenic outcome of
dysregulated WDR26 in comparison to CTLH complex members to support the premise
that WDR26 exists within the CTLH complex.
To achieve this, analysis of a large-scale cancer genomics data set was performed to
assess the tissue distribution of mutations in WDR26 in comparison to other core CTLH
members. Using the International Cancer Genome Consortium (ICGC), data was
collected assessing the number tissues harbouring a point mutation in WDR26, RanBPM,
and Core CTLH members, MAEA and RMND5A. The number of nonsynonymous
mutations with a predicted functional impact found in these genes in primary tumours
were 94, 87, 83, and 10 respectively. All four members showed mutations occurring in
liver, colorectal or stomach tissue at the highest frequency, accounting for 40% to 70% of
total mutations (Figure 3.1). Having such a highly correlated pattern in targeted tissues
suggest that these proteins may act within the same pathway, or complex. As a control,
these were compared to the tumour suppressors p53 and phosphatase and tensin homolog
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(PTEN). PTEN displayed mutations commonly occurring in breast, stomach and
esophageal tissue while p53 was commonly mutated in uterine, brain and breast tissue,
and contained 651 and 3966 mutations respectively (Figure 3.1). Having a unique
distribution of mutations shared by all core CTLH members that differs from two
independent proteins suggests that WDR26 may share a similar function to the CTLH
complex and that this result is not due to a sampling bias if liver, colorectal and stomach
were to be the largest data sets in the ICGC.

3.2.2

WDR26 is localized to the cytoplasm and interacts with the
CTLH complex

A recent study using the Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) database was performed assessing functional protein associations and
determined that WDR26 was part of an interacting network with RanBPM and other
CTLH members (56). However, in addition to known interactions, the STRING database
uses computational methods to predict protein interactions, thus WDR26 interaction with
the CTLH complex still needed to be confirmed. Previous studies investigating the
cellular localization of RanBPM determined it was a nucleocytoplasmic protein and was
found to localize with chromatin in the nucleus, as well as the plasma membrane (8, 22).
The localization of other CTLH members has yet to be reported, however the LisH
domain has been reported to be an important factor in determining localization and was
shown to promote localization to actin fibers in the cytoplasm (106). Preliminary
immunofluorescence experiments in our laboratory has indicated that all CTLH members
are nucleocytoplasmic with a higher tendency to reside in the nucleus, with the exception
of Muskelin, which was primarily cytoplasmic (120).
To determine the localization of WDR26, immunofluorescence experiments were
performed by imaging ectopically expressed WDR26 in wild-type HeLa cells. A FLAGtagged WDR26 was transfected into wild-type HeLa cells and its subcellular localization
evaluated 48h post-transfection. WDR26 was found to be primarily cytoplasmic, with up
to 10 % imaged cells showing equal localization to the nucleus and cytoplasm (Figure
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Figure 3.1. Analysis of tissues affected from alterations of WDR26 and core CTLH
members as determined by the international cancer genome consortium. Using the
International Cancer Genome Consortium (ICGC), the number of primary tumours, per
tissue type containing nonsynonymous point mutations in either WDR26 (94) or RanBPM
(87) and the Core CTLH members RMND5A (10) and MAEA (83) were scored and
arranged in a pie chart with the percentage of tissues containing mutations ordered from
most to least prevalent. Primary tumours, per tissue type, containing nonsynonymous
point mutations in PTEN (651) and TP53 (3966) were collected and compared to as
controls.
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3.2A, B). This suggests WDR26 is a nucleocytoplasmic protein and localizes to the same
compartments as core CTLH members, thus could interact with the CTLH complex.
To determine if WDR26 associates with the CTLH complex, co-immunoprecipitation
(Co-IP) experiments were carried out. FLAG-tagged WDR26 transiently transfected into
wild-type HeLa cells was immunoprecipitated (IP) and the samples were analyzed using
Western blot to evaluate the Co-IP of CTLH members. These immunoprecipitation
experiments were compared to a control which consisted of un-transfected wild-type
HeLa cells subjected to the same FLAG IP. All CTLH members tested, RanBPM,
MAEA, RMND5A and Muskelin co-immunoprecipitated with FLAG-WDR26 while
none of them were found in the un-transfected sample (Figure 3.2C). These results
suggest that WDR26 associates with the CTLH complex ex vivo.

3.3 Endogenous Axin Co-Immunoprecipitates with CTLH
members
Previously, a study identified that mammalian WDR26 interacts with Axin1 through a
co-immunoprecipitation of ectopically expressed WDR26 and Axin in HEK 293 cells
(63). In addition to this, STRING analysis of Axin immunocomplexes predicted the
interaction of WDR26 with the CTLH complex, also predicted all CTLH complex
members to be an interacting partner with Axin1 (56). To confirm this, additional Co-IP
experiments were performed to IP endogenous RanBPM from wild-type HeLa cells,
followed by Western blot analysis. In the first instance, endogenous RanBPM
immunoprecipitates were analyzed to test the presence of Axin. RanBPM was
successfully immunoprecipitated and showed endogenous Axin to Co-IP (Figure 3.3A).
This IP was repeated and endogenous Axin again co-immunoprecipitated, along with
CTLH members ARMC8α and MAEA (Figure 3.3B). These results suggest that not only
WDR26 but the whole CTLH complex is associating with Axin.
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Figure 3.2 WDR26 localizes to the cytoplasm and interacts with the CTLH complex.
(A) Representative images of ectopically expressed WDR26 in HeLa wild-type cells.
pCMV-FLAG-WDR26 was transfected in wild-type HeLa cells. Cells were fixed 24 h
after transfection and incubated using a FLAG antibody and then an Alexa Fluor 488
secondary antibody (green). Nuclei were stained with DAPI (blue). (B) Subcellular
localization was scored as either N>>C (nuclear much greater than cytoplasmic), N>C
(nuclear greater than cytoplasmic), N=C (nuclear equal to cytoplasmic), N<C
(cytoplasmic greater than nuclear) and N<<C (cytoplasmic much greater than nuclear).
Data represents averages from three separate experiments each assessing a total of 50
cells. (C) Western blot analysis of co-immunoprecipitation of CTLH members following
immunoprecipitation of FLAG tagged WDR26. pCMV-FLAG-WDR26 was transfected
into HeLa wild-type cells and harvested after 24 hours. pCMV-FLAG-WDR26
transfected (+) or untransfected (-) extracts were subjected to immunoprecipitation with a
FLAG antibody. Immunoprecipitates were analyzed by western blot.
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Figure 3.3 Endogenous Axin Co-Immunoprecipitates with RanBPM and core
CTLH members. (A) Western blot analysis was performed to assess the coimmunoprecipitation of Axin following the immunoprecipitation of endogenous
RanBPM. (B) A second immunoprecipitation of endogenous RanBPM was performed to
confirm Axin Co-IP and assess the co-immunoprecipitation with core CTLH complex
members. All immunoprecipitations were performed using 1mg of protein while 5%
(50µg) was loaded for the input and were analyzed using primary Axin, RanBPM,
MAEA and ARMC8α/β antibodies.
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3.4 RanBPM negatively regulates β-catenin protein levels
3.4.1 β-catenin is elevated in RanBPM downregulated cells
Our laboratory previously performed micro-array analysis on HeLa and HCT116 cells
stably expressing RanBPM shRNA and found that downregulation of RanBPM resulted
in dysregulation of genes within the Wnt pathway (19). A previous study has also shown
that downregulation of RanBPM results in an increase in the β-catenin homologue in
Drosophila, suggesting that the dysregulation of Wnt genes was due to alteration of βcatenin levels (13). To determine the effect of RanBPM expression on β-catenin protein
levels, extracts from various cell lines with stably downregulated RanBPM were analyzed
by Western blot. Using RanBPM shRNA, or control shRNA HeLa and HCT 116 cell
lines, a modest, yet significant increase in β-catenin was found in RanBPM shRNA cells
compared to the control cells (Figure 3.4A, B). Additionally, 3T3 mouse embryonic
fibroblasts (MEFs) from RanBPM knockout mice displayed a similar significant increase
of β-catenin compared to wild-type MEFs (Figure 3.4C). Lastly, RanBPM siRNA was
used to transiently knock down RanBPM expression in CaCo-2 cells. Again, there was a
significant increase in β-catenin protein levels in the RanBPM downregulated CaCo-2
cells compared to cells transfected with scrambled siRNA (Figure 3.4D). To confirm the
specificity of the effect on β-catenin, RanBPM expression was restored in HeLa RanBPM
shRNA cells. Increasing amounts of HA-tagged RanBPM, (from 1 – 3 μg), was
transfected into the RanBPM shRNA cells. Upon overexpression of RanBPM, there was
a significant decrease, up to 50%, in β-catenin levels (Figure 3.5). Together these results
suggest RanBPM functions as a negative regulator of β-catenin.

3.4.2 RanBPM may regulate β-catenin indirectly through the
proteasome
Negative regulation of the canonical Wnt signalling pathway involves the
polyubiquitination of β-catenin and its subsequent degradation by the proteasome (82).
While this ubiquitination is most commonly performed by the E3 ubiquitin ligase βTrCP, additional ligases have been shown to target β-catenin for ubiquitination (82-84).
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To determine whether RanBPM is regulating β-catenin levels through the ubiquitinmediated proteasomal degradation pathway, similar to the regulation of gluconeogenic
enzymes by the GID complex, RanBPM shRNA HeLa cells were used to assess β-catenin
protein levels under conditions of proteasomal inhibition to determine if the loss of
RanBPM affected β-catenin degradation. To accomplish this, RanBPM shRNA and nontargeting control shRNA HeLa cells were treated with MG132, a proteasomal inhibitor,
or with the vehicle, DMSO. Under normal conditions, MG132 inhibition of the
proteasome will prevent the degradation of ubiquitinated proteins leading to their
accumulation in the cell. However, cells lacking E3 ubiquitin ligase activity, due to the
loss of RanBPM, would lack this accumulation. Cells were treated with 10 μM of MG132
or DMSO and were harvested 16 h after treatment and analyzed through Western blot.
HeLa cells expressing RanBPM shRNA showed a minimal, and non-significant increase
in β-catenin protein levels under proteasomal inhibition, whereas the control shRNA cells
showed over a 2-fold increase in β-catenin protein levels upon proteasomal inhibition,
compared to vehicle treated cells (Figure 3.6). This suggests β-catenin may be regulated
by the proteasome indirectly through RanBPM.

3.5 CTLH member RMND5A negatively regulates β-catenin
protein levels
Thus far, evidence that the CTLH complex regulates β-catenin has been limited to
RanBPM. To support that this regulation occurs through the CTLH complex activity,
additional CTLH members must demonstrate a similar effect on β-catenin protein levels.
Our laboratory utilized CRISPR-Cas9 to target and knockout RMND5A in HeLa wildtype cells. RMND5A is the mammalian homologue of GID2, the RING domain
containing subunit conferring the E3 ubiquitin ligase activity of the GID complex which
is essential for in vivo ubiquitination of FBPase by the GID complex (57, 58). The high
conservation of its mammalian homologue, RMND5A, also containing a RING domain,
suggests that it functions as the E3 ubiquitin ligase of the CTLH complex. While
RMND5A has demonstrated ubiquitination activity in Xenopus laevis, it has yet to be
confirmed as the source of E3 ubiquitination activity of the CTLH complex (104).
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Figure 3.4 β-Catenin protein levels are elevated in RanBPM downregulated cell
lines. Western blot analysis of β-catenin protein levels in HeLa (A) and HCT 116 (B) cell
lines stably expressing RanBPM shRNA or control shRNA. (C) Similar analysis was
made using immortalized mouse embryonic fibroblasts (MEFs) that are RanBPM
deficient. (D) CaCo-2 cells were transfected with 10 nM of RanBPM targeting siRNA or
scrambled non-targeting siRNA and were harvested 24 h post-transfection and β-catenin
protein levels were assessed through Western blot. All western blot analyses were
performed using up to a total of 50 μg of protein and using primary β-catenin, RanBPM
and Actin antibodies. Relative β-catenin protein levels were quantified by normalizing βcatenin to actin and expressing values relative to control (or wild-type) cells which were
given a value of 1. Quantifications are shown with error bars indicating SD. A twosample t-test, assuming equal variance, was used to determine significance. * p<0.05;
*** p<0.001
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Figure 3.5 Overexpression of RanBPM decreases β-catenin protein levels. (Left)
Western blot analysis of β-catenin protein levels in HeLa cells stably expressing
RanBPM shRNA following the re-expression of RanBPM. An increasing amount, to 3
μg, of pCMV-HA-RanBPM was transfected into HeLa shRanBPM cells and were
harvested 24 h post-transfection. Up to 50 μg of protein was used for analysis and blots
were analyzed using primary β-catenin, RanBPM and Actin antibodies. Relative βcatenin protein levels were quantified by normalizing β-catenin to actin and expressing
values relative to untreated cells which were given a value of 1. Quantifications are
shown with error bars indicating SD. A two-sample t-test, assuming equal variance, was
used to determine significance. *** p<0.001; ns not significant.
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To determine the effect of the knockout of RMND5A on β-catenin expression, a cohort
of monoclonal RMND5A knockout cell lines were generated and screened for β-catenin
protein levels through Western blot. The initial screen revealed a ubiquitous increase in
endogenous β-catenin levels in all RMND5A knockout clones compared to parental
HeLa cells (Figure 3.7). To confirm this result, two clones, HeLa RMND5A -/- clones 16
and 18 (RMND5A-/- C16 and RMND5A-/- C18), were selected for further analysis and
confirmed a consistent and significant increase in β-catenin protein levels compared to
HeLa CRISPR control cells (Figure 8A, B). β-catenin protein regulation was rescued by
ectopically expressing HA-RMND5A in RMND5A-/- C16 cells for 24 h, decreasing βcatenin back to levels observed in HeLa CRISPR control cells (Figure 8C, D). These
results demonstrate that endogenous β-catenin levels are downregulated by RMND5A
expression suggesting RMND5A plays a key role in regulating β-catenin.

3.6 CTLH complex members affect β-catenin target gene
expression
3.6.1 Downregulation of RanBPM leads to increased β-catenin
nuclear localization
In the canonical Wnt signalling pathway, the cellular levels of β-catenin are primarily
controlled by ubiquitination and proteasomal degradation (82). Only when β-catenin can
escape this regulation will it begin to accumulate (90). Once cytoplasmic levels have
increased, β-catenin will translocate into the nucleus and upregulate its target genes (9193). To determine whether the CTLH complex affects β-catenin target gene expression,
we sought to test whether the increased β-catenin levels observed in RanBPM/RMND5A
downregulated cells coincided with an increase in nuclear localization. To test this,
immunofluorescence experiments were performed imaging endogenous β-catenin in
RanBPM shRNA and control shRNA HeLa cells (Figure 3.9A). These analyses revealed
a significant increase in β-catenin nuclear localization in the RanBPM downregulated
cells compared to control cells (Figure 3.9B). This demonstrates that the loss of β-catenin
regulation by RanBPM results in increased nuclear translocation.
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3.6.2 RMND5A regulates β-catenin target gene expression
β-catenin target genes are regulated by the TCF/LEF transcription factors, which under
normal conditions interact with TLE1/Groucho proteins and recruit transcriptional
repressors to Wnt responsive elements and inhibit gene expression (94, 96). When βcatenin enters the nucleus, it will displace TLE1/Groucho from the TCF/LEF
transcription factors, recruit transcriptional co-activators and enable WRE target gene
expression (97, 98). Given that the loss of RanBPM and CTLH member RMND5A have
been demonstrated to increase β-catenin protein levels and its nuclear localization, it is
hypothesized that β-catenin target gene expression will be altered upon dysregulation of
the CTLH complex.
To determine if the regulation of β-catenin by the CTLH complex translated into a
change in target gene expression, a luciferase assay was performed using RMND5A-/C16 HeLa cell line along with a β-catenin activated reporter luciferase (pBARL), which
contains 12 consecutive TCF/LEF response elements, the target motif of β-catenin
upstream of a Promega MinP minimal promoter (94). The pBARL plasmid, a βgalactosidase internal control and either pCMV-Empty Vector or HA-RMND5A were cotransfected into RMND5A-/- C16, and cells were harvested 48 h after transfection. Under
these conditions, the luciferase activity provides a trackable change in TCF/LEF
mediated gene expression in response to RMND5A. Upon reintroduction of RMND5A,
there was a significant decrease, up to 70%, in relative fluorescence (Figure 3.10). This
result suggests that the regulation of the CTLH complex on β-catenin negatively affects
its downstream target gene expression.
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Figure 3.6 β-Catenin is regulated by the proteasome through RanBPM. A) Control
shRNA (shControl) and RanBPM shRNA (shRanBPM) HeLa cells were treated with 10
μM of MG132 or DMSO, as a vehicle, for 24 h. Cells were harvested in whole cell
extract buffer and up to 50 μg of protein was used for Western blot analysis and blots
were hybridized with β-catenin, RanBPM and Actin antibodies. B) Relative β-catenin
protein levels were quantified by normalizing β-catenin to actin and expressing values
relative to DMSO treated cells which were given a value of 1. Quantifications are shown
with error bars indicating SD. A two-sample t-test, assuming equal variance, was used to
determine significance. ** p<0.01; ns not significant.
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Figure 3.7 RMND5A regulates β-catenin protein levels. A) CRISPR-Cas9 was used to
create monoclonal RMND5A knockouts in HeLa cells. A cohort of RMND5A knockout
clones were harvested in whole cell extract, and up to 50 μg of protein was prepared and
analyzed by Western blot. Proteins were probed for using primary β-catenin, vinculin and
RMND5A antibodies. In bold are the two HeLa RMND5A knockout clones selected for
further experimentation B) Relative β-catenin protein levels were quantified by
normalizing β-catenin to vinculin and expressing values relative to wild-type cells which
were given a value of 1. Significance was not determined.
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Figure 3.8 Rescue of RMND5A restores β-catenin Regulation. (A)Whole cell extracts
of two HeLa RMND5A CRISPR-Cas9 clones (Clones 16 and 18; C16 and C18) and a
pool of HeLa cells that underwent the same CRISPR-Cas9 selection process absent guide
RNA (HeLa EV Pool) were prepared and analyzed by Western blot using primary βcatenin, Actin and RMND5A antibodies. (B) Relative β-catenin protein levels were
quantified by normalizing β-catenin to actin and expressing values relative to HeLa EV
Pool, which were given a value of 1. (C) pCGN-HA-RMND5A was transfected into
HeLa RMND5A-/- clone 16 cells to rescue the effect on β-catenin protein levels. These
cells were harvest and analyzed by Western blot using primary β-catenin, Actin and
RMND5A antibodies (D) Relative β-catenin protein levels were quantified by
normalizing β-catenin to actin and expressing values relative to HeLa Empty Vector
Pool, which were given a value of 1. A two-sample t-test, assuming equal variance, was
used to determine significance. * p < 0.05
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Figure 3.9 Downregulation of RanBPM causes increase nuclear localization of βcatenin. A) Representative images of nuclear (DAPI) and endogenous β-catenin staining
in control shRNA and RanBPM shRNA HeLa cells. Nuclear staining was performed
using DAPI (blue). β-catenin staining was performed by using a primary mouse- βcatenin antibody and a secondary mouse antibody conjugated to Alexa Fluor 488 (green).
(B) Quantification of the HeLa nuclear staining was performed by counting 50 cells and
determining the relative total cell and nuclear intensity using ImageJ. After accounting
for background signal intensity, the nuclear intensity was compared to the total intensity
to determine the relative percentage of nuclear β-catenin levels. The percent of nuclear βcatenin levels were expressed relative to control shRNA cells, which were given a value
of 1. A two-sample t-test, assuming equal variance, was used to determine significance.
*** p < 0.001
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3.7 The CTLH complex may promote β-catenin ubiquitination
Canonical ubiquitination of β-catenin involves the poly-ubiquitination of lysine 19 (K19)
and lysine 49 (K49) by the E3 ubiquitin ligase β-TrCP, marking it for proteasomal
degradation (105). Since the CTLH complex is an E3 ubiquitin ligase, it is hypothesized
that the regulation of β-catenin by the CTLH complex is through ubiquitination. To
determine whether the CTLH complex is targeting β-catenin for degradation, in vitro
experiments were performed to assess β-catenin ubiquitination by the CTLH complex. To
accomplish this, an HA-tagged ubiquitin expression plasmid was transfected into wildtype and RMND5A-/- C16 HeLa cells. In addition, these cells were treated with the
proteasomal inhibitor, MG132. Using a tagged ubiquitin molecule in combination with a
proteasomal inhibitor allows for the visualization of ubiquitination of a protein. Through
inhibition of the proteasome, ubiquitinated forms of β-catenin would begin to
accumulate, whereas cells lacking CTLH complex activity due to the loss of RMND5A,
would not show the ubiquitinated forms of β-catenin.
These cells were treated with 10 μM of MG132 for 8 hours and harvested 24 hours posttransfection. Endogenous β-catenin was immunoprecipitated and analyzed through
Western blot. In the wild-type HeLa cells expressing ubiquitin, after hybridization with a
primary HA antibody a laddering, or smear characteristic of ubiquitination was revealed
above 100 kDa, the approximate molecular weight of β-catenin (Figure 3.11). This
pattern was also visible in the immunoprecipitate of the RMND5A knockout cells
expressing ubiquitin, however the ubiquitin smear was greatly reduced. These were
compared to parental cells not transfected with HA-ubiquitin in which there was no
laddering present. The reduced ubiquitin laddering in the RMND5A knockout cell line
suggests RMND5A and the CTLH complex functions to promote the ubiquitination of βcatenin.
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Figure 3.10 RMND5A regulates β-catenin target gene expression. HeLa RMND5A
knockout clone 16 cells were transfected with a luciferase plasmid containing a β-catenin
target motif (TCF/LEF promoter), a β-galactosidase internal control, and either pCMVEmpty Vector or pCGN-HA-RMND5A. Cells were harvested and analyzed 48 h posttransfection using a Promega Luciferase Assay System and Promega Beta-Glo on an
Orion II Microplate Luminometer. Relative β-catenin gene expression was normalized to
the β-galactosidase internal control and expressed relative to the RMND5A knockout
cells transfected with pCMV-Empty Vector, which was given a value of 1. ****
p<0.0001.
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Figure 3.11 The CTLH complex may promote ubiquitination of β-catenin. Western
blot analysis of the immunoprecipitation of ubiquitinated β-catenin. An HA-tagged
Ubiquitin plasmid was transfected into HeLa wild-type cells and HeLa RMND5A
knockout clone 16. These cells were treated with 10 μM of MG132 and harvested 24 h
post-transfection. Endogenous β-catenin was immunoprecipitated from 500 μg of
untransfected (-) and transfected (+) cell lysates and analyzed by western blot. The input
(5% total protein) and immunoprecipitates were analyzed by western blot to assess
immunoprecipitation using a β-catenin antibody and an HA antibody to assess
ubiquitination of β-catenin.
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Chapter 4
4

Discussion

4.1 Summary of findings
The goal of the study was to characterize the regulation of β-catenin protein levels and
downstream target gene expression by the CTLH complex. It was hypothesized that the
CTLH complex is regulating the Wnt signalling pathway through the targeting of βcatenin for degradation. Specifically, we sought to confirm that the putative complex
member, WDR26, was in fact part of the CTLH complex, to determine the effect of the
CTLH complex on β-catenin protein levels, and to investigate whether this effect
translated to a change in β-catenin target gene expression. In summary, we found that
WDR26 interacts with RanBPM and core CTLH members, and that the CTLH complex
forms a complex with Axin. We determined that RanBPM and RMND5A negatively
regulate β-catenin protein levels, and that this was mediated through the proteasome.
Additionally, it was shown that loss of RanBPM results in an increase in β-catenin
nuclear localization. Lastly, it was found that RMND5A regulates β-catenin target gene
expression. Whether this regulation is direct or indirect is still unknown, but preliminary
data suggests the CTLH complex may promote the ubiquitination of β-catenin.

4.2 WDR26 interacts with the CTLH complex
While the CTLH complex has long been thought to function as an E3 ubiquitin ligase,
similar to its yeast counterpart, the GID complex, it has only very recently been
demonstrated to contain E3 ubiquitin ligase activity (62). In this discovery its first
confirmed substrate was also identified as Hbp1, however previous studies have
implicated it in the regulation of β-catenin (62-64). A recent study has demonstrated that
WDR26, a putative member of the CTLH complex downregulates β-catenin when
overexpressed (63). Although interactome studies have predicted WDR26 to exist as part
of the CTLH complex, this needed to be confirmed (56). In Chapter 3.2.1, we
investigated the tissue distribution of mutations in WDR26 in comparison to core CTLH
members and found that WDR26 mutations have a similar tissue distribution as those of
other CTLH complex members RanBPM, RMND5A and MAEA. Proteins within the
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same pathway, when dysregulated in theory could promote tumour development at the
same primary site, thus this highly correlated pattern of mutation distribution suggests
WDR26 may be part of the CTLH complex. In Chapter 3.2.2, we investigated the
interaction of WDR26 with the CTLH complex ex vivo. WDR26 was found to interact
with multiple members of the CTLH complex, including Muskelin. While it was initially
thought that Muskelin replaced WDR26 in the CTLH complex compared to the yeast
GID complex (54), these results suggest WDR26 does interact with the CTLH complex.

4.3 The CTLH complex regulates the canonical Wnt
signalling pathway through proteasomal degradation
While the main mechanisms of regulation of β-catenin is through the Axin degradation
complex in the canonical Wnt pathway, additional means to regulate β-catenin have been
uncovered. As previously stated, the canonical regulation of β-catenin involves the
sequential phosphorylation by CK1 and GSK3β, which serves as a signal to recruit βTrCP promoting the ubiquitination and degradation of β-catenin by the proteasome (8082). While initially it was thought that nuclear β-catenin was transported back into the
cytosol to be targeted by the Axin degradation complex, there have been studies
identifying nuclear components to additionally target β-catenin (107). Nuclear β-catenin
was shown to be regulated by a separate phosphorylation mediated ubiquitination event
performed by protein kinase C delta type (PKCδ) and tripartite motif-containing protein
33 (TRIM33) respectively (108). In a similar mechanism as the Axin degradation
complex, PKCδ directly phosphorylates nuclear β-catenin at serine 715 (S715), which is
required for the subsequent ubiquitination by TRIM33 (108). Additionally, TRIM33
ubiquitination of β-catenin was shown to be independent of GSK3β and β-TrCP activity
(108). A separate study has identified nuclear β-catenin to be regulated through
methylation (109). In Xenopus, it was demonstrated that lysine demethylase 2a and lysine
demethylase 2b (Kdm2a/b) were also required for regulation of nuclear β-catenin (109).
Lysine demethylase 2a/b were shown to interact with the fourth and fifth armadillo
repeats of β-catenin and were responsible for demethylating specific lysine residues in
this region that were targets of ubiquitination (109). Additional studies have revealed
other cytoplasmic E3 ubiquitin ligases to target and regulate β-catenin, including Seven
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in Absentia Homologue 1 (SIAH-1), the E3 ubiquitin ligase identified by Differential
Display (EDD), and Gene for Apoptosis and Differentiation in Epithelia 1 (JADE-1) (83,
84, 110). SIAH-1 and JADE-1 have both been shown to directly ubiquitinate β-catenin
promoting it for degradation, however EDD ubiquitination has been shown to increase
the stability of β-catenin (83, 84, 110). Having multiple ubiquitination pathways
regulating β-catenin stability implies its physiological importance, and further
understanding these pathways is important to understand the relation between β-catenin
and oncogenesis.
In Chapters 3.4 and 3.5, we investigated the role of CTLH members RanBPM and
RMND5A and their relation to β-catenin. Individually, the loss of these two members
showed a significant increase in β-catenin protein levels, and this affect was rescued
when these proteins were re-expressed. As these two members serve as the scaffold to the
CTLH complex and the RING domain subunit responsible for E3 ligase activity
respectively, the loss of either would result in less complex formation, less active
complex, allowing β-catenin to escape regulation and accumulate. Additionally, a
previous study has demonstrated that the overexpression of WDR26 promoted
degradation of β-catenin (63). Together, RanBPM, RMND5A and WDR26 individually
regulating β-catenin levels strongly suggests this regulation is being performed by the
CTLH complex.
In Chapter 3.4 we also investigated whether the loss of RanBPM would affect β-catenin
degradation under conditions of proteasomal inhibition. Treating control cells expressing
RanBPM with the proteasomal inhibitor MG132 showed a significant increase in βcatenin protein levels. This is in contrast to cells with stably downregulated RanBPM,
which did not show a similar increase in β-catenin upon proteasomal inhibition. This
likely means that downregulation of RanBPM resulted in reduced ubiquitination of βcatenin, thus decreasing the effect observed in under proteasomal impairment. This
suggests RanBPM may function to promote the ubiquitination of β-catenin promoting it
for degradation by the proteasome.
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While dysregulation of CTLH complex members has been shown to alter β-catenin
protein levels, this on its own does not confirm its role in the Wnt signalling pathway. To
address this, in Chapter 3.6.1 we investigated the localization of β-catenin upon RanBPM
loss of expression. It was found that decreased RanBPM expression resulted in an
increased nuclear localization of β-catenin compared to control cells. Beta-catenin fulfills
two separate functions, one in the Wnt signalling pathway, the other in adherens junction
formation. (71, 72). These regulations involve two different pools of β-catenin localized
in different cellular compartments. Its role in the Wnt signalling pathway involves the
migration of β-catenin to the nucleus to regulate gene transcription, while adherens
junctions are localized to the cell membrane (111). Thus, our results demonstrating an
increased nuclear localization of β-catenin upon RanBPM downregulation suggests it
affects its role in the Wnt signalling pathway.
Therefore, in Chapter 3.6.2, we investigated whether RMND5A, the subunit of the CTLH
complex conferring E3 ubiquitination enzymatic activity, affects the target gene
expression of β-catenin. Using a luciferase plasmid responsive to the β-catenin target
TCF/LEF, the downstream activation of β-catenin target genes were assessed in response
to re-expression of RMND5A in CRISPR-Cas9 RMND5A knockout HeLa cells. Upon
the re-expression of RMND5A in these cells there was a drastic decrease in the β-catenin
reporter activation, indicating RMND5A is involved in regulating β-catenin target gene
expression.
In Chapter 3.7 we sought to determine whether the CTLH complex was affecting the
ubiquitination of β-catenin through in vitro ubiquitination assays. Endogenous β-catenin
was immunoprecipitated from extracts of wild-type and RMND5A CRISPR-Cas9
knockout HeLa cells transfected with a tagged-ubiquitin following proteasomal
inhibition. Treating these cells with MG132 would lead to the accumulation of
ubiquitinated products that would be visible as a laddering or smear through western blot.
It was found that there was a drastic decrease in visible ubiquitinated β-catenin in the
RMND5A knockout cells compared to wild-type HeLa cells. There was still
ubiquitination of β-catenin in the RMND5A knockout HeLa cells, however this is
expected as additional E3 ubiquitin ligases are known to target β-catenin for
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ubiquitination (83, 84, 109). The appreciable decrease in ubiquitinated β-catenin upon the
loss of RMND5A suggests that the CTLH complex is enhancing the ubiquitination of βcatenin, however whether this is a direct or indirect function of the CTLH complex has
yet to be determined.

4.4 Regulation of β-catenin is independent of the Axin
degradation complex
In Chapter 3.3 we demonstrated that endogenous Axin co-immunoprecipitates with
RanBPM and core CTLH complex members. Although this suggests that the complex
interacts with Axin, it is suspected that the regulation of β-catenin by the CTLH complex
is independent of the Axin degradation complex. A previous study has shown that the
regulation of β-catenin by WDR26 was independent of GSK3β activity (63). WDR26
was overexpressed in the presence and absence of a GSK3β inhibitor, and it was found
that WDR26 decreased β-catenin under both conditions. If WDR26 activity was
dependent on GSK3β phosphorylation, then abolishing GSK3β activity would eliminate
the ability for WDR26 to regulate β-catenin. Additionally, in chapter 3.4.1 while
investigating the effect of RanBPM on β-catenin, we used two cell lines (HCT 116 and
CaCo-2) that have previously been characterized to contain mutations in β-catenin or
components of the Axin degradation complex (112, 113). HCT 116 contains a
heterozygous deletion of codon 45 in exon 3, which results in a deletion of serine 45
(112). Serine 45 is one of the phosphorylation sites of CK1 of the Axin complex and is
required for GSK3β phosphorylation. CaCo-2 cells are characterized as containing two
mutations. First, there is a guanine to cytosine transversion resulting in a change from
glycine to alanine in codon 245, within the Arm repeat region of exon 5 (112).
Additionally, CaCo-2 cells have a truncating mutation in APC in exon 16 in addition to
loss of heterozygosity (113). The mutation in β-catenin occurs at the site of APC binding,
and while it has not been fully characterized, the structural change is theorized to
decrease APC binding to β-catenin (112). More significantly, the loss of APC due to
truncation would result in loss of control of normal β-catenin signalling (114). The
mutations characterized in both HCT 116 and CaCo-2 cells cause a functional loss of βcatenin regulation mediated by the Axin degradation complex. If the effect of RanBPM
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on β-catenin was mediated through the Axin degradation complex, then this would be
abolished in these cell lines. The change in β-catenin in these cell lines in response to
RanBPM suggests it is regulating β-catenin in a novel mechanism, different than the
canonical pathway.
Disruption of the canonical Wnt signalling pathway is often associated with colorectal
carcinoma resulting from loss of function mutations in APC (117). This is consistent with
the results presented in Chapter 3.2.1, where the tissue distribution of mutations
displayed colorectal tissue to contain a high number of mutations in WDR26, RanBPM,
MAEA andRMND5A. Interestingly, these CTLH complex members were also found
mutated in liver tumours at a higher rate. While Wnt signalling in carcinogenesis is most
commonly associated with colorectal cancer, previous studies have showed activating
mutations in β-catenin to contribute to the pathogenesis of hepatocellular carcinoma
among many cancer types (118, 119). While many components of the Wnt signalling
pathway may contribute to various forms of cancer, mutations in CTLH complex
members leading to loss of CTLH regulation may contribute to Wnt signalling
hyperactivation and the progression of these cancers.

4.5 Limitation of the study and future work
Previous studies along with the results presented here suggest that both WDR26 and
Muskelin may exist in the CTLH complex, despite initial reports suggesting Muskelin
replaces WDR26. While the exact topology of the CTLH complex is not fully
understood, previous work in our laboratory has identified CTLH complex members as
nucleocytoplasmic proteins (120). Interestingly however, RanBPM, RMND5A and
MAEA were primarily nuclear, while Muskelin and WDR26 were primarily cytoplasmic
(120). It is possible that there are multiple forms of the CTLH complex, containing either
WDR26, Muskelin, or both depending on the compartmentalization of the complex as
well as temporal expression of these members. To fully understand the function of the
CTLH complex, further studies should focus on determining where these proteins
colocalize within the cell, and whether WDR26 and Muskelin localize to the CTLH
complex simultaneously or whether these interactions are mutually exclusive.
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When performing the β-catenin activated luciferase assay, the reporter activation was
normalized to a β-galactosidase (β-Gal) reporter that was co-transfected to control for
transfection efficiency. Initially this experiment was performed using RanBPM shRNA
HeLa cells co-transfected with the β-catenin reporter as well as a Renilla reporter (pRL).
Repeatedly, it was found that the re-expression of RanBPM was altering the pRL
activation making it unreliable to use to normalize the samples (Supplemental Figure 1).
To avoid this, the experiment was changed to use RMND5A CRISPR-Cas9 knockout
HeLa cells instead, however the same effect on pRL was observed upon re-expression of
RMND5A. This suggests the CTLH complex may alter pRL expression, and an
alternative control was needed. While β-Gal is a less commonly used reporter for
luciferase assays compared to a dual-luciferase system, it did provide consistent results
that were not influenced by RMND5A. However, using β-Gal as a control, we were
unable to simultaneously measure β-catenin activation and the negative control in the
same sample through a dual luciferase system. The measurements had to be taken in
parallel with separate sample preparations measured at the same time. Although this was
not the ideal system, the results were consistent between replicates.
The data presented in Chapters 3.4 and 3.5 strongly implicates RanBPM and RMND5A
in the regulation of β-catenin protein levels, however the mechanism behind this
regulation is still unknown. In Chapter 3.7 we determined RMND5A affects β-catenin
ubiquitination by visualizing ectopically expressed HA-ubiquitination of endogenous βcatenin that was immunoprecipitated under proteasomal inhibition. Our results displayed
a decreased presence of HA-ubiquitin upon the knockout of RMND5A. While these
results suggest RMND5A functions to enhance the ubiquitination of β-catenin, whether
this effect is direct or indirect is uncertain. To determine whether the CTLH complex is
directly ubiquitinating β-catenin, an in vitro ubiquitination assay could be performed
where purified members of the CTLH complex are immunoprecipitated and incubated
with purified β-catenin along with all required components of the ubiquitination reaction.
If ubiquitinated under these conditions, it would suggest the CTLH complex is directly
ubiquitinating β-catenin.
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Another possibility is that the CTLH complex is regulating β-catenin through an
intermediate protein or complex that regulates elements upstream of β-catenin. Recently,
a member of our laboratory performed a large-scale proteomic analysis to assess global
changes in ubiquitination upon the loss of CTLH members. Initial results have identified
a few potential targets for ubiquitination that have been shown to interact with
components of the Wnt pathway (Maitland, unpublished). The first target identified is
tankyrase-2 (Tnks2) which functions to poly-ADP-ribosylate (PARylate) Axin,
promoting it for degradation (115). An upregulation of Tnks2 due to loss of RanBPM
theoretically would result in a decrease in Axin allowing for β-catenin to accumulate. A
second potential target identified for CTLH ubiquitination was the receptor-interaction
protein kinase 4 (RIPK4). RIPK4 has been shown to promote Wnt signalling by
phosphorylating dishevelled and promoting Wnt receptor activation (116). Upregulation
of RIPK4 due to loss of RanBPM would stabilize β-catenin mediated through Wnt
receptor activation, however whether this activation occurs independent of the Axin
degradation is unknown.
A final option is that the CTLH complex is targeting an interacting partner with Axin.
Although our data suggests that this regulation is independent of the Axin degradation
complex, it was shown that the regulation of β-catenin by WDR26 required interaction
with Axin1 (63). In this case, the CTLH complex may be regulating an interacting partner
with Axin, different than those in the canonical degradation complex, that also influence
β-catenin stability. See figure 4.1 below for an overview of possible targets of CTLH
ubiquitination that mediate the regulation of β-catenin. Further studies should be
performed to identify and validate additional targets of CTLH ubiquitination that may
mediate the regulation of β-catenin.
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Figure 4.1 Potential mechanisms of CTLH mediated β-catenin regulation. A) The
CTLH complex may indirectly regulate β-catenin protein levels by targeting Tnks2
(Tankyrase-2) or RIPK4 (receptor interaction protein kinase 4) which are known to
regulate components of the Axin degradation complex. Alternatively, the CTLH complex
may regulate a currently unidentified target that may directly regulate β-catenin. B) The
CTLH complex may target a component within the Wnt signalling pathway that is
upstream to β-catenin, including an interacting partner with Axin apart from CK1 (casein
kinase 1), APC (adenomatous polyposis coli) or GSK3β (glycogen synthase kinase 3beta). C) The CTLH complex may directly target β-catenin for degradation.
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4.6 Conclusion
Overall, this study was performed to investigate the regulation of β-catenin and the Wnt
signalling pathway by the CTLH complex. This study has further implicated the CTLH
complex to regulate β-catenin, as well as Wnt target gene expression. While further
studies need to be performed to elucidate the mechanism behind the regulation of βcatenin, the results demonstrated here suggest a novel tumour suppressive role of the
CTLH complex as a negative regulator of the Wnt signalling pathway.
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